The motion focuses on the Independent Medicines and Medical Devices Safety Review's recommendations, particularly on mesh surgery. Emma highlights the need for a timeline for action, transparency in payments to clinicians, data collection accuracy, informed consent before using mesh implants, and establishing specialist treatment centres.

Commends Emma Hardy for bringing this debate forward, highlighting the suffering of constituents due to mesh surgery complications.

Supports Emma Hardy's motion and raises concerns about mesh procedures affecting men, causing significant harm and in some cases suicide.

Encourages women to speak up about their health issues while acknowledging the institutional challenges they face. Criticises recent comments from Government that shift responsibility to individual women.

Concerned about clinical pressure to lift moratorium on mesh implant procedures despite no change in circumstances over the past 18 months.

Expresses concern that some surgeons who performed mesh surgeries are now leading figures in mesh removal centres and continue to deny their role in causing harm.

She discusses the importance of establishing an independent patient safety commissioner and stresses that the role must be effective in hearing patients' voices and stopping the use of harmful medical devices. Mrs May also raises concerns about redress for affected individuals, noting the high cost and stress associated with legal action and advocating for a more supportive system. She further highlights the ongoing issue of sodium valproate's risks to pregnant women and their children, emphasising the need for comprehensive information and education.

Mr Shannon intervenes to discuss the needs of affected individuals in Northern Ireland who are unable to work due to physical difficulties resulting from pelvic mesh implants and seeks assurances that government benefits will be available to them. He also addresses the breakdown in marriages caused by these issues and calls for support in addressing such consequences.

Ms Bardell intervenes, agreeing with Mrs May on the need to address institutional cultures that discourage learning from mistakes and emphasises the necessity of a patient safety commissioner who can help shift away from a litigious culture towards one that promotes patient-centred care.

Thanked colleagues for securing the debate and praised Baroness Cumberlege for her review. Highlighted the ongoing problems with medical devices such as Primodos, valproate, and vaginal mesh. Paid tribute to campaigners who have fought tirelessly on these issues over many years. Shared a personal story about her mother’s experience with surgical mesh implants, emphasising the devastating impact it had on her life. Raised concerns about women being forced to trust the same surgeons for removal of mesh who originally implanted it without addressing their health problems adequately. Called for NHS England and the Minister to provide patients with genuine choices regarding where they receive treatment and from whom. Mentioned ongoing issues with valproate prescriptions, emphasising that around 400 babies are still born each year affected by this drug despite existing safeguards.

Honoured the previous speakers for their powerful campaigning, thanked Baroness Cumberlege for her review on women’s medicine oversight, commended the Minister for patient safety initiatives but expressed concern about the lack of a redress scheme. Criticised the NHS's handling of sodium valproate warnings and called for more stringent prescription rules to eliminate harm to babies born from mothers taking valproate.

I am grateful for the opportunity to speak in such an important debate... Ministers should do the right thing and give them the justice and the recompense that they deserve.

The hon. Lady mentions the expert working group’s report, which was, as she rightly says, universally panned in this Chamber. The interesting thing is that the Cumberlege review took place after the expert working group. It had a look at the report and also came to the conclusion that it was not worth the paper it was written on.

My constituent Mrs Jennifer Meakin was prescribed Primodos during her pregnancy, which resulted in severe birth defects for her child Daniel. Hormone pregnancy tests came to market in the early 1960s and approximately 1 million prescriptions were dispensed. Despite warnings about their unreliability and potential harm, these tests continued to be used until June 1975 when a general warning was issued by the Committee on Safety of Medicines. The report recommends establishing specialist centres for affected families and an ex gratia scheme for discretionary payments. Families have suffered stress and psychological harm due to the scandal. I urge the Government to establish a support scheme for Primodos victims, similar to what has been done for thalidomide victims.

I discuss sodium valproate's impact on women and their children, particularly my constituent Bethany Dodgson who is affected by foetal valproate syndrome. Despite campaigning efforts to warn of the risks, more children are still being harmed due to lack of awareness. I endorse Baroness Cumberlege’s report recommendations for a patient safety commissioner, redress agency, and patient reference group. The Government must act swiftly to prevent further harm to women and ensure their voices are heard in future medical decisions.

Stressed the importance of the debate, highlighted a constituent's story to illustrate the impact of vaginal mesh operations. Emphasised that clinicians need to be held accountable for dismissing patients' concerns and not listening to them. Argued for proper implementation of Baroness Cumberlege’s review recommendations, focusing on redress for those affected.

Discusses the devastating impact of the drug Primodos on countless families, highlighting the case of his constituent Nan McGradie and her daughter Michelle. Emphasises that despite evidence of potential dangers in 1967, no official warnings were issued until eight years later. Mentions systematic regulatory failures by government drug vigilance authorities responsible for ensuring thalidomide tragedy could never happen again. Advocates for the Government to accept responsibility and implement recommendations from Baroness Cumberlege’s independent medicines and medical devices safety review.

Raises concerns about the establishment and effectiveness of mesh centres, questioning their comprehensiveness and whether surgeons who previously denied issues with mesh procedures are now attempting to remediate them. Emphasises the need for research into safer methods of mesh removal or alternative materials that could dissolve harmlessly within the body. Points out discrepancies in statistical data regarding women readmitted to hospital following mesh sling implantation, calling for urgent implementation of Cumberlege’s recommendations and financial redress for affected women.

Intervenes to emphasise the human impact of mesh complications, highlighting increased suicide rates among women suffering from such issues, urging quicker action on implementing recommendations to prevent further tragedies.

She expressed disappointment at the lack of progress on implementing Baroness Cumberlege’s recommendations, particularly concerning sodium valproate. She urged the Government to provide a full response this year and address specific recommendations such as establishing an independent redress agency, setting up a registry for pregnant women taking anti-epileptic drugs, and improving pregnancy prevention plans.

She appealed to MPs speaking from home to be mindful of the time constraints facing those in the Chamber. She reminded them that speeches can often be more effective when shorter.

He welcomed the opportunity to discuss Baroness Cumberlege’s review and thanked her for her work, as well as those who bravely shared their experiences regarding mesh implants. He supported the establishment of an independent commissioner for patient safety and welcomed NHS England's announcement to commission specialist services for women with complications from mesh implants.

Pays tribute to hon. Members Emma Hardy, Cat Smith, Alec Shelbrooke for their work on women’s health issues and the APPG for valproate and other anti-epileptic drugs in pregnancy. Acknowledges the importance of listening to patients' concerns, especially regarding sodium valproate. Emphasises the need for a redress scheme similar to thalidomide victims’ compensation to support those affected by sodium valproate during pregnancy.

Congratulates Emma Hardy on the debate and highlights the ongoing issue of hormone-based pregnancy test drug Primodos causing harm to babies. Criticises the Government's reluctance to acknowledge evidence linking Primodos with deformities, urging the Minister to implement recommendations from Baroness Cumberlege’s review for compensation for victims.

Paid tribute to Members for their speeches and to campaigners who raised awareness. Focused on mesh implants, citing Nicole MacNiven's case as an example of the distress caused by such implants. Emphasised the report’s timeline highlighting dismissed warning signs and disregarded patient concerns, leading to delayed harm avoidance measures. Criticised the MHRA for its slow response compared to the Scottish Government in suspending mesh use. Quoted Baroness Cumberlege's conclusion that there is a healthcare system unable to promptly identify and respond to safety concerns. Urged the new Secretary of State for Health and Social Care to reform the regulatory system. Supported the recommendation for an independent patient safety commissioner, opposing the UK Government’s proposal for the Health Secretary to appoint one due to recent scandals. Highlighted steps taken by the Scottish Government to support mesh implant victims through a mesh fund, reimbursement for past removal surgeries, and establishment of comprehensive services with multidisciplinary teams.

Discussed the underlying issues in disasters involving vaginal mesh, sodium valproate, and Primodos. Emphasised licensing and regulatory failures, lack of accurate information for informed consent, poor adverse event reporting systems, and doctors not listening to affected women. Focused on vaginal mesh complications due to initial research not identifying long-term issues, leading to a shift to this approach as it appeared safer initially despite later problems. Criticised the federal drug administration in America and EMA/MHRA for approving tapes without further trials. Praised Dr Wael Agur’s development of Scottish patient decision aids but stressed the need for consensus and routine use. Highlighted risks with sodium valproate, citing lack of reporting as a critical issue. Urged improvement in the yellow card system to detect and act on adverse events. Called for the Government to outline plans for reforming licensing and regulation of new drugs/devices and supporting affected women through removal/remedial surgery and financial redress.

The speaker recognises the contributions of several Members, including the hon. Member for Washington and Sunderland West, highlighting their commitment to patient safety and justice. He also discusses the importance of communication across Government and health services, stressing the need for a proper redress scheme for affected families. The speaker calls for the government to revisit its rejection of an independent taskforce and a redress agency.

The Minister highlights that the Government has implemented several recommendations, including establishing a patient safety commissioner through the Medicines and Medical Devices Bill. She also mentions ongoing work to improve patient involvement in regulatory processes and establish a medical device information system. However, she states that certain recommendations such as a redress agency will not be accepted.

Thanked participants in the debate, emphasised the importance of implementing recommendations from Baroness Cumberlege's review to prevent future harm. Highlighted issues with valproate medication and called for additional funding for research into alternative treatments. Emphasised the risk of repeating past mistakes and urged the Government to act on recommendations. Stressed the need for a moratorium on mesh implant procedures until a retrospective audit is completed.